Development and Validation of the Chinese Version of the Quality of Recovery-40 Questionnaire.

IF 2.3 3区医学 Q2 HEALTH CARE SCIENCES & SERVICES

Therapeutics and Clinical Risk Management Pub Date : 2020-12-02 eCollection Date: 2020-01-01 DOI:10.2147/TCRM.S281572

Yeyang Chen, Junfu Wang, Siyu Liu, Weikun Lai, Jinlu Liu, Zhen Wang, Bopei Li, Yuantian Mao, Ye Wang, Guofei Deng, Junqiang Chen

{"title":"Development and Validation of the Chinese Version of the Quality of Recovery-40 Questionnaire.","authors":"Yeyang Chen, Junfu Wang, Siyu Liu, Weikun Lai, Jinlu Liu, Zhen Wang, Bopei Li, Yuantian Mao, Ye Wang, Guofei Deng, Junqiang Chen","doi":"10.2147/TCRM.S281572","DOIUrl":null,"url":null,"abstract":"Purpose: The present study aimed to develop the official Chinese version of the QoR-40 (QoR-40C) and to test its reliability, validity, and responsiveness.Patients and methods: A systematic translation procedure was established and performed to develop the QoR-40C from the original English QoR-40 version. After the pilot study, 223 surgical patients were administered the QoR-40C at four time points. The validity, reliability, and responsiveness were assessed to validate the QoR-40C.Results: The test-retest reliability of the QoR-40C in the morning and afternoon of the third day after surgery was 0.917 (P < 0.001). The split-half reliability for all domains was 0.938 in the morning of the third day after surgery. The median item-to-own dimension and total score of Cronbach's α for internal consistency of the QoR-40C at different assessment time points were more than 0.70. All the correlation coefficients between each subscale and the QoR-40 total score showed good correlation and were greater than those for other subscales in the morning of the third day after surgery. Furthermore, in the morning of the third day after surgery, the QoR-40C total score was moderately positively correlated with the SF-36 score (ρ = 0.575, P < 0.001), while the QoR-40C score was negatively correlated with the visual analogue scale (VAS) score (ρ = -0.299, P < 0.001). The factor loadings of each item were within the required range. A statistically significant difference was observed in the QoR-40C total scores before and after the surgery (P < 0.001) with the standardized responsive mean (SRM) of 0.51.Conclusion: The QoR-40C showed good reliability, validity, and responsiveness and was appropriate to be used as a quality of life measurement questionnaire for patients after surgery in China.","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"16 ","pages":"1165-1173"},"PeriodicalIF":2.3000,"publicationDate":"2020-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4c/99/tcrm-16-1165.PMC7719329.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutics and Clinical Risk Management","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/TCRM.S281572","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: The present study aimed to develop the official Chinese version of the QoR-40 (QoR-40C) and to test its reliability, validity, and responsiveness.

Patients and methods: A systematic translation procedure was established and performed to develop the QoR-40C from the original English QoR-40 version. After the pilot study, 223 surgical patients were administered the QoR-40C at four time points. The validity, reliability, and responsiveness were assessed to validate the QoR-40C.

Results: The test-retest reliability of the QoR-40C in the morning and afternoon of the third day after surgery was 0.917 (P < 0.001). The split-half reliability for all domains was 0.938 in the morning of the third day after surgery. The median item-to-own dimension and total score of Cronbach's α for internal consistency of the QoR-40C at different assessment time points were more than 0.70. All the correlation coefficients between each subscale and the QoR-40 total score showed good correlation and were greater than those for other subscales in the morning of the third day after surgery. Furthermore, in the morning of the third day after surgery, the QoR-40C total score was moderately positively correlated with the SF-36 score (ρ = 0.575, P < 0.001), while the QoR-40C score was negatively correlated with the visual analogue scale (VAS) score (ρ = -0.299, P < 0.001). The factor loadings of each item were within the required range. A statistically significant difference was observed in the QoR-40C total scores before and after the surgery (P < 0.001) with the standardized responsive mean (SRM) of 0.51.

Conclusion: The QoR-40C showed good reliability, validity, and responsiveness and was appropriate to be used as a quality of life measurement questionnaire for patients after surgery in China.

Abstract Image

查看原文本刊更多论文

康复质量-40问卷中文版的开发与验证。

目的：本研究旨在开发官方中文版 QoR-40（QoR-40C），并测试其信度、效度和反应度：患者和方法：根据 QoR-40 英文原版建立并执行了系统的翻译程序，以开发 QoR-40C。试点研究结束后，223 名手术患者在四个时间点接受了 QoR-40C 测试。对QoR-40C的有效性、可靠性和响应性进行了评估，以验证QoR-40C的有效性：QoR-40C 在术后第三天上午和下午的重测信度为 0.917（P < 0.001）。术后第三天上午，所有维度的分半信度为 0.938。QoR-40C在不同评估时间点的内部一致性Cronbach's α中位数项目对项目维度和总分均大于0.70。在术后第三天上午，各分量表与 QoR-40 总分之间的相关系数均显示出良好的相关性，且大于其他分量表。此外，术后第三天早上，QoR-40C 总分与 SF-36 评分呈中度正相关（ρ = 0.575，P < 0.001），而 QoR-40C 评分与视觉模拟量表（VAS）评分呈负相关（ρ = -0.299，P < 0.001）。各项目因子载荷均在要求范围内。手术前后的 QoR-40C 总分差异有统计学意义（P < 0.001），标准化反应平均值（SRM）为 0.51：QoR-40C具有良好的信度、效度和反应度，适合作为中国术后患者的生活质量测量问卷。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutics and Clinical Risk Management HEALTH CARE SCIENCES & SERVICES-

CiteScore

4.80

自引率

3.60%

发文量

139

审稿时长

16 weeks

期刊介绍： Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines, therapeutic and surgical interventions in all clinical areas. The journal welcomes submissions covering original research, clinical and epidemiological studies, reviews, guidelines, expert opinion and commentary. The journal will consider case reports but only if they make a valuable and original contribution to the literature. As of 18th March 2019, Therapeutics and Clinical Risk Management will no longer consider meta-analyses for publication. The journal does not accept study protocols, animal-based or cell line-based studies.